Shopping Cart 0
Cart Subtotal
USD 0

Bayer AG (BAYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Bayer AG (Bayer) carries out the research, development, production and commercialization of products for human and animal health care, and agriculture. It provides medicines for cardiovascular diseases, women's health, cancer, hematology, ophthalmology and other indications. The company's product portfolio includes prescription products, specialty therapeutics, animal health care products, diagnostic imaging equipment, nonprescription (over-the-counter-OTC) products, seeds, crop protection solutions and nonagricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, Germany.

Bayer AG (BAYN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 8

Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10

Bayer AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 11

Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12

Bayer AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 13

Bayer AG, Medical Devices Deals, 2012 to YTD 2018 15

Bayer AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 16

Bayer AG, Pharmaceuticals & Healthcare, Deal Details 20

Asset Purchase 20

Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 20

Venture Financing 22

BlueRock Therapeutics Raises USD225 Million in Series A Financing 22

Private Equity 23

Bayer to Raise USD3.69 Billion in Private Placement of Shares 23

Bayer May Sell Dermatology Business 25

Sobera Capital Acquires Minority Stakes In Biopharma Companies From Bayer Pharma And Bayer HealthCare 26

Partnerships 27

ChromoTek Enters Into Licensing Agreement With Bayer For Cell Cycle Chromobody Technology 27

Bayer and MD Anderson Cancer Center Enter into Agreement 28

Bayer and PeptiDream Enter into Partnership 29

Bayer Enters into Co-Development Agreement with Loxo Oncology 30

Bayer and Vanderbilt University Medical Center Enter into Research Agreement 31

leadXpro Enters into Agreement with Bayer 32

University of Pittsburgh and Bayer Form Research Collaboration Agreement 33

Bayer Enters into Partnership with Evotec 34

Bayer Enters into Agreement with National Surgical Adjuvant Breast and Bowel Project 35

Bayer Enters into Co-Development Agreement with Regeneron Pharma 36

Bayer and CRISPR Therapeutics Forms Joint Venture 37

Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 38

Proteros Biostructures Enters into Research Agreement with Bayer 39

Bayer HealthCare Enters Co-Development Agreement with University of Oxford 40

Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 41

arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 42

Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 43

Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 44

Bayer HealthCare Pharma And Broad Institute Enter Into Agreement To Develop Cancer Therapy 45

Bayer Enters Into Co-Marketing Agreement With Ildong Pharma For OTC Drugs 46

Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 47

Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 48

X-Chem and Bayer Pharma Expand Agreement 49

Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 50

Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 51

Algeta Exercises Option Agreement With Bayer To Co-Promote Alpharadin 53

Bayer Healthcare Enters Into Co-Development Agreement With Tsinghua University 54

Licensing Agreements 55

Bayer Enters into Licensing Agreement with Haplogen and Evotec 55

Luye Pharma and Luye Supply to Enter into Agreement with Bayer 56

Bayer Enters into Licensing Agreement with Progenics Pharma 57

X-Chem Enters into Licensing Agreement with Bayer Pharma for Drug Discovery Program 58

Taisho Pharma Enters into Licensing Agreement with Bayer Yakuhin 59

Bayer Enters into Licensing Agreement with ERS Genomics 60

Bayer Pharma Enters Into Licensing Agreement With X-Chem For Drug Discovery Program 61

Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library 62

Oxford Pharmascience Enters Into Licensing Agreement With Bayer Consumer Care 63

Equity Offering 64

Bayer Plans to Raise USD7 Billion in Rights Offering of Shares 64

Crispr Therapeutics Prices Private Placement of Shares for USD35 Million 65

Debt Offering 66

Bayer to Raise USD2.5 Billion in Private Placement of 4.25% Bonds Due 2025 66

Bayer to Raise USD1.74 Billion in Private Placement of 2.125% bonds Due 2029 67

Bayer to Raise USD1.25 Billion in Private Placement of 3.5% Bonds Due 2021 68

Bayer to Raise USD2 Billion in Private Placement of 4.875% Bonds Due 2048 69

Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2021 70

Bayer to Raise USD3.5 Billion in Private Placement of 4.375% Bonds Due 2028 71

Bayer to Raise USD2.03 Billion in Private Placement of 1.5% bonds Due 2026 72

Bayer to Raise USD2.25 Billion in Private Placement of 3.875% Bonds Due 2023 73

Bayer to Raise USD1 Billion in Private Placement of 4.625% Bonds Due 2038 74

Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2023 75

Bayer to Raise USD870 Million in Private Placement of Bonds Due 2022 76

Bayer to Raise USD1.16 Billion in Private Placement of 0.625% bonds Due 2022 77

Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 78

Bayer Raises USD1.4 Billion in Public Offering of 2.375% Hybrid Bonds Due 2075 79

Bayer Prices 1.25% Bonds Due 2023 for USD623.5 Million 80

Bayer Raises USD1.5 Billion in Public Offering of 3% Bonds Due 2021 81

Bayer Raises USD2 Billion in Public Offering of 2.375% Bonds Due 2019 82

Bayer Raises USD500 Million in Public Offering of Notes Due 2016 83

Bayer Raises USD400 Million in Public Offering of Bonds Due 2017 84

Bayer Raises USD1.75 Billion in Public Offering of 3.375% Bonds Due 2024 85

Bayer Raises USD850 Million in Public Offering of 1.5% Bonds Due 2017 86

Bayer Raises USD2.38 Billion in Public Offering of 3% Bonds Due 2075 87

Bayer Raises USD2 Billion in Public Offering of 3.75% Bonds Due 2074 89

Bayer Raises USD677.3 Million in Public Offering of Notes Due 2016 91

Bayer Raises USD1.02 Billion in Public Offering of 1.125% Notes Due 2018 92

Bayer Raises USD1.02 Billion in Public Offering of 1.875% Bonds Due 2021 93

Bayer Completes Public Offering Of Notes Due 2019 For USD 102 Million 94

Bayer Completes Public Offering Of Notes Due 2016 For USD 259 Million 95

Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For USD 363 Million 96

Asset Transactions 97

LEO Pharma Acquires Prescription Dermatology Portfolio from Bayer 97

Recordati Acquires Consumer Health Brands from Bayer Consumer Care 98

Famar Health Care Services Acquires Pointe-Claire Manufacturing Site from Bayer 99

WellSpring Pharma Acquires Bactine 100

Alvogen Acquires Five Hormonal Products from Bayer Pharma 101

Bayer Korea to Sell Mercilon 102

Alliance Pharma Acquires Rights To Irenat From Bayer 103

Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For USD 4.8 Million 104

Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 105

Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 106

Acquisition 107

Bayer to Acquire Minority Stake in CRISPR Therapeutics for USD35 Million 107

Bayer Acquires Dihon Pharma for USD586 Million 108

Bayer Nordic Completes Acquisition Of Algeta For USD 2.58 Billion 109

Bayer Completes Acquisition Of Steigerwald Arzneimittelwerk, Herbal Treatments Provider 111

Bayer Completes Acquisition Of 96.4% Stake In Conceptus For USD 1.1 Billion 112

Delpharm Completes Acquisition Of Bayer Sante Familiale, Consumer Care Division Of Bayer 114

Nomad Bioscience Acquires Icon Genetics From Bayer Innovation 115

Bayer AG-Key Competitors 116

Bayer AG-Key Employees 117

Bayer AG-Locations And Subsidiaries 118

Head Office 118

Other Locations & Subsidiaries 118

Joint Venture 127

Recent Developments 129

Financial Announcements 129

May 03, 2018: Bayer: Operational business held back by currency effects Major progress with Monsanto acquisition 129

Oct 26, 2017: Bayer: Sales and earnings increased 133

Apr 27, 2017: Strong start to the year for Bayer 138

Corporate Communications 141

Sep 27, 2018: Bayer appoints Sebastian Guth to lead Pharmaceuticals business in the Americas 141

Sep 13, 2018: Bayer appointed Stefan Oelrich to Board of Management 142

Nov 15, 2017: Heiko Schipper is the new CEO and Head of the Consumer Health Division at Bayer 144

Sep 29, 2017: Bayer helping people affected by the earthquake in Mexico 145

Sep 12, 2017: Wolfgang Nickl to be new Chief Financial Officer at Bayer 146

Apr 27, 2017: Supervisory Board of Bayer extends service contract of CFO Johannes Dietsch to the end of May 2018 147

Jan 17, 2017: Dr. Carsten Brunn to Lead Bayer's Pharmaceuticals Business in the Americas Region 148

Legal and Regulatory 149

Sep 21, 2018: NHS wins landmark ruling against pharma companies over AMD drug 149

Aug 22, 2017: Bayer will continue to work constructively with the European Commission 150

Government and Public Interest 151

Mar 28, 2018: Life Science Leaders Gather at Medidata NEXT Basel and Frankfurt to Examine New Opportunities to Improve Clinical Development and Better Patient Lives 151

Nov 17, 2017: Christine Eischen Receives 2017 AACR-Bayer Innovation and Discovery Grant 152

Jul 18, 2017: Two Indian researchers win Grants to advance Hemophilia Research & Care 153

Jul 11, 2017: Bayer Awards $2 Million in Grants to Advance Hemophilia Research and Patient Care 155

Feb 22, 2017: Another record year for Bayer good progress with the acquisition of Monsanto 156

Product News 160

12/07/2017: Bayer to Highlight New Research on copanlisib at ASH 2017 160

11/01/2017: Janssen to Present Abstracts on XARELTO at ASH 2017 161

10/30/2017: Bayer receives FDA approval for Xarelto 10 mg once daily for the extended treatment of venous thromboembolism 165

10/25/2017: Study: Rx Drug Lawsuit Ads Cause Spike in Reports of Patient Health Incidents, Deaths 166

09/15/2017: Bayer receives positive CHMP opinion for rivaroxaban 10 mg once daily for the extended prevention of venous thromboembolism 167

09/14/2017: Bayer Receives FDA Approval for Aliqopa (copanlisib) 60 mg vial for Injection in Adults with Relapsed Follicular Lymphoma after Two Prior Systemic Therapies 169

08/22/2017: Landmark GARFIELD-AF Data to be Presented at ESC 2017 Congress Will Feature 1-year Outcomes on 52,000 Prospective Patients and the First Insights From the Registry on Health Economics in Atrial Fibrillation (AF) 170

07/26/2017: Compugen Provides Update on its Immuno-Oncology Drug Candidate CGEN-15001T 173

07/21/2017: Bayers Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent Placement 174

07/02/2018: Compugen Welcomes FDA Clearance of Bayer's IND Application for BAY 1905254 176

06/28/2017: U.S. FDA Grants Priority Review of XARELTO (rivaroxaban) sNDA for a 10 mg Dose to Reduce the Risk of Recurrent Venous Thromboembolism 177

05/17/2018: Bayer to Present One Poster on Rogaratinib at ASCO 2018 179

05/17/2017: Bayer Receives FDA Priority Review For Investigational Anti-Cancer Compound Copanlisib 180

03/18/2017: Bayer's Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study 182

Product Approvals 184

Dec 11, 2017: Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD) 184

Nov 06, 2017: Bayer Submits Application for Marketing Approval of Rivaroxaban for Patients with Coronary or Peripheral Artery disease to European Medicines Agency 185

Apr 28, 2017: Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism 187

Clinical Trials 189

Oct 09, 2018: Bayer to showcase latest oncology research on copanlisib at ESMO 2018 Congress 189

May 17, 2018: Bayer to Present on Copanlisib Hydrochloride at ASCO 2018 190

Apr 18, 2018: Evotec and Bayer advance third endometriosis programme into Phase I clinical development 191

Apr 17, 2018: Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy 192

Dec 07, 2017: Thirteen abstracts highlighting data from Bayer's rivaroxaban will be presented at ASH 2017, two addressing cancer-associated thrombosis 193

Nov 10, 2017: Bayers Xarelto(rivaroxaban) Significantly Reduces the Risk of Major Amputation by 70% in Patients with Peripheral Artery Disease 195

Oct 05, 2017: Bayers NAVIGATE ESUS study halted early as it indicated comparable efficacy between treatment arms 196

Sep 01, 2017: Bayer to Present Data on Copanlisib at ESMO 2017 Congress 197

Sep 01, 2017: Bayer to Present Data on Rogaratinib at ESMO 2017 Congress 198

Aug 27, 2017: Bayer's Xarelto significantly lowered the combined risk of stroke, cardiovascular death and heart attack in patients with chronic coronary or peripheral artery disease by 24% 199

Aug 21, 2017: New XARELTO (rivaroxaban) Data at ESC Congress 2017 Includes Late-Breaking Results from Landmark Phase 3 COMPASS Study 201

Jul 24, 2017: Evotec and Bayer Advance Endometriosis Programme into Phase I Clinical Development and Extend Alliance 207

Jul 03, 2017: New Data from Bayers Portfolio in Thrombosis and Hemophilia to be Presented at ISTH 2017 208

Mar 31, 2017: Phase II Copanlisib Data Show Durable Tumor Response in Indolent Non-Hodgkins Lymphoma 210

Mar 06, 2017: EINSTEIN CHOICE Study with Bayer's Rivaroxaban Accepted for Late-Breaking Clinical Trial Presentation at ACC.17 212

Feb 08, 2017: Phase III COMPASS study with Bayer's Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early 215

Other Significant Developments 217

Oct 17, 2018: Bayer provides disaster reliefImmediate support for earthquake victims in Indonesia company makes EUR 115,000 available in immediate assistance for people impacted in Central Sulawesi province 217

Aug 30, 2018: Bayer accelerates six new startups 218

May 31, 2018: ORNL ramps up production of key radioisotope for cancer-fighting drug 219

Dec 01, 2017: Bayer invests in differentiated drug pipeline with over 50 projects focused on high unmet medical needs 220

Appendix 223

Methodology 223

About GlobalData 223

Contact Us 223

Disclaimer 223


List Of Figure

List of Figures

Bayer AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Bayer AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10

Bayer AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 11

Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12

Bayer AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 13

Bayer AG, Medical Devices Deals, 2012 to YTD 2018 15


List Of Table

List of Tables

Bayer AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10

Bayer AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 11

Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12

Bayer AG, Deals By Therapy Area, 2012 to YTD 2018 13

Bayer AG, Medical Devices Deals, 2012 to YTD 2018 15

Bayer AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 16

Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 20

BlueRock Therapeutics Raises USD225 Million in Series A Financing 22

Bayer to Raise USD3.69 Billion in Private Placement of Shares 23

Bayer May Sell Dermatology Business 25

Sobera Capital Acquires Minority Stakes In Biopharma Companies From Bayer Pharma And Bayer HealthCare 26

ChromoTek Enters Into Licensing Agreement With Bayer For Cell Cycle Chromobody Technology 27

Bayer and MD Anderson Cancer Center Enter into Agreement 28

Bayer and PeptiDream Enter into Partnership 29

Bayer Enters into Co-Development Agreement with Loxo Oncology 30

Bayer and Vanderbilt University Medical Center Enter into Research Agreement 31

leadXpro Enters into Agreement with Bayer 32

University of Pittsburgh and Bayer Form Research Collaboration Agreement 33

Bayer Enters into Partnership with Evotec 34

Bayer Enters into Agreement with National Surgical Adjuvant Breast and Bowel Project 35

Bayer Enters into Co-Development Agreement with Regeneron Pharma 36

Bayer and CRISPR Therapeutics Forms Joint Venture 37

Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 38

Proteros Biostructures Enters into Research Agreement with Bayer 39

Bayer HealthCare Enters Co-Development Agreement with University of Oxford 40

Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 41

arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 42

Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 43

Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 44

Bayer HealthCare Pharma And Broad Institute Enter Into Agreement To Develop Cancer Therapy 45

Bayer Enters Into Co-Marketing Agreement With Ildong Pharma For OTC Drugs 46

Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 47

Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 48

X-Chem and Bayer Pharma Expand Agreement 49

Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 50

Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 51

Algeta Exercises Option Agreement With Bayer To Co-Promote Alpharadin 53

Bayer Healthcare Enters Into Co-Development Agreement With Tsinghua University 54

Bayer Enters into Licensing Agreement with Haplogen and Evotec 55

Luye Pharma and Luye Supply to Enter into Agreement with Bayer 56

Bayer Enters into Licensing Agreement with Progenics Pharma 57

X-Chem Enters into Licensing Agreement with Bayer Pharma for Drug Discovery Program 58

Taisho Pharma Enters into Licensing Agreement with Bayer Yakuhin 59

Bayer Enters into Licensing Agreement with ERS Genomics 60

Bayer Pharma Enters Into Licensing Agreement With X-Chem For Drug Discovery Program 61

Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library 62

Oxford Pharmascience Enters Into Licensing Agreement With Bayer Consumer Care 63

Bayer Plans to Raise USD7 Billion in Rights Offering of Shares 64

Crispr Therapeutics Prices Private Placement of Shares for USD35 Million 65

Bayer to Raise USD2.5 Billion in Private Placement of 4.25% Bonds Due 2025 66

Bayer to Raise USD1.74 Billion in Private Placement of 2.125% bonds Due 2029 67

Bayer to Raise USD1.25 Billion in Private Placement of 3.5% Bonds Due 2021 68

Bayer to Raise USD2 Billion in Private Placement of 4.875% Bonds Due 2048 69

Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2021 70

Bayer to Raise USD3.5 Billion in Private Placement of 4.375% Bonds Due 2028 71

Bayer to Raise USD2.03 Billion in Private Placement of 1.5% bonds Due 2026 72

Bayer to Raise USD2.25 Billion in Private Placement of 3.875% Bonds Due 2023 73

Bayer to Raise USD1 Billion in Private Placement of 4.625% Bonds Due 2038 74

Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2023 75

Bayer to Raise USD870 Million in Private Placement of Bonds Due 2022 76

Bayer to Raise USD1.16 Billion in Private Placement of 0.625% bonds Due 2022 77

Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 78

Bayer Raises USD1.4 Billion in Public Offering of 2.375% Hybrid Bonds Due 2075 79

Bayer Prices 1.25% Bonds Due 2023 for USD623.5 Million 80

Bayer Raises USD1.5 Billion in Public Offering of 3% Bonds Due 2021 81

Bayer Raises USD2 Billion in Public Offering of 2.375% Bonds Due 2019 82

Bayer Raises USD500 Million in Public Offering of Notes Due 2016 83

Bayer Raises USD400 Million in Public Offering of Bonds Due 2017 84

Bayer Raises USD1.75 Billion in Public Offering of 3.375% Bonds Due 2024 85

Bayer Raises USD850 Million in Public Offering of 1.5% Bonds Due 2017 86

Bayer Raises USD2.38 Billion in Public Offering of 3% Bonds Due 2075 87

Bayer Raises USD2 Billion in Public Offering of 3.75% Bonds Due 2074 89

Bayer Raises USD677.3 Million in Public Offering of Notes Due 2016 91

Bayer Raises USD1.02 Billion in Public Offering of 1.125% Notes Due 2018 92

Bayer Raises USD1.02 Billion in Public Offering of 1.875% Bonds Due 2021 93

Bayer Completes Public Offering Of Notes Due 2019 For USD 102 Million 94

Bayer Completes Public Offering Of Notes Due 2016 For USD 259 Million 95

Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For USD 363 Million 96

LEO Pharma Acquires Prescription Dermatology Portfolio from Bayer 97

Recordati Acquires Consumer Health Brands from Bayer Consumer Care 98

Famar Health Care Services Acquires Pointe-Claire Manufacturing Site from Bayer 99

WellSpring Pharma Acquires Bactine 100

Alvogen Acquires Five Hormonal Products from Bayer Pharma 101

Bayer Korea to Sell Mercilon 102

Alliance Pharma Acquires Rights To Irenat From Bayer 103

Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For USD 4.8 Million 104

Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 105

Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 106

Bayer to Acquire Minority Stake in CRISPR Therapeutics for USD35 Million 107

Bayer Acquires Dihon Pharma for USD586 Million 108

Bayer Nordic Completes Acquisition Of Algeta For USD 2.58 Billion 109

Bayer Completes Acquisition Of Steigerwald Arzneimittelwerk, Herbal Treatments Provider 111

Bayer Completes Acquisition Of 96.4% Stake In Conceptus For USD 1.1 Billion 112

Delpharm Completes Acquisition Of Bayer Sante Familiale, Consumer Care Division Of Bayer 114

Nomad Bioscience Acquires Icon Genetics From Bayer Innovation 115

Bayer AG, Key Competitors 116

Bayer AG, Key Employees 117

Bayer AG, Subsidiaries 118

Bayer AG, Joint Venture 127

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Bayer AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Bayer AG (Bayer) carries out the research, development, production and commercialization of products for human and animal health care, and agriculture. It provides medicines for cardiovascular diseases, women's health, cancer, hematology, ophthalmology and other indications. The company's product portfolio includes prescription products, specialty therapeutics, animal health care products, diagnostic imaging equipment, nonprescription (over-the-counter-OTC) products, seeds, crop protection solutions and nonagricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, Germany.

Bayer AG (BAYN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 8

Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10

Bayer AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 11

Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12

Bayer AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 13

Bayer AG, Medical Devices Deals, 2012 to YTD 2018 15

Bayer AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 16

Bayer AG, Pharmaceuticals & Healthcare, Deal Details 20

Asset Purchase 20

Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 20

Venture Financing 22

BlueRock Therapeutics Raises USD225 Million in Series A Financing 22

Private Equity 23

Bayer to Raise USD3.69 Billion in Private Placement of Shares 23

Bayer May Sell Dermatology Business 25

Sobera Capital Acquires Minority Stakes In Biopharma Companies From Bayer Pharma And Bayer HealthCare 26

Partnerships 27

ChromoTek Enters Into Licensing Agreement With Bayer For Cell Cycle Chromobody Technology 27

Bayer and MD Anderson Cancer Center Enter into Agreement 28

Bayer and PeptiDream Enter into Partnership 29

Bayer Enters into Co-Development Agreement with Loxo Oncology 30

Bayer and Vanderbilt University Medical Center Enter into Research Agreement 31

leadXpro Enters into Agreement with Bayer 32

University of Pittsburgh and Bayer Form Research Collaboration Agreement 33

Bayer Enters into Partnership with Evotec 34

Bayer Enters into Agreement with National Surgical Adjuvant Breast and Bowel Project 35

Bayer Enters into Co-Development Agreement with Regeneron Pharma 36

Bayer and CRISPR Therapeutics Forms Joint Venture 37

Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 38

Proteros Biostructures Enters into Research Agreement with Bayer 39

Bayer HealthCare Enters Co-Development Agreement with University of Oxford 40

Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 41

arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 42

Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 43

Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 44

Bayer HealthCare Pharma And Broad Institute Enter Into Agreement To Develop Cancer Therapy 45

Bayer Enters Into Co-Marketing Agreement With Ildong Pharma For OTC Drugs 46

Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 47

Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 48

X-Chem and Bayer Pharma Expand Agreement 49

Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 50

Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 51

Algeta Exercises Option Agreement With Bayer To Co-Promote Alpharadin 53

Bayer Healthcare Enters Into Co-Development Agreement With Tsinghua University 54

Licensing Agreements 55

Bayer Enters into Licensing Agreement with Haplogen and Evotec 55

Luye Pharma and Luye Supply to Enter into Agreement with Bayer 56

Bayer Enters into Licensing Agreement with Progenics Pharma 57

X-Chem Enters into Licensing Agreement with Bayer Pharma for Drug Discovery Program 58

Taisho Pharma Enters into Licensing Agreement with Bayer Yakuhin 59

Bayer Enters into Licensing Agreement with ERS Genomics 60

Bayer Pharma Enters Into Licensing Agreement With X-Chem For Drug Discovery Program 61

Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library 62

Oxford Pharmascience Enters Into Licensing Agreement With Bayer Consumer Care 63

Equity Offering 64

Bayer Plans to Raise USD7 Billion in Rights Offering of Shares 64

Crispr Therapeutics Prices Private Placement of Shares for USD35 Million 65

Debt Offering 66

Bayer to Raise USD2.5 Billion in Private Placement of 4.25% Bonds Due 2025 66

Bayer to Raise USD1.74 Billion in Private Placement of 2.125% bonds Due 2029 67

Bayer to Raise USD1.25 Billion in Private Placement of 3.5% Bonds Due 2021 68

Bayer to Raise USD2 Billion in Private Placement of 4.875% Bonds Due 2048 69

Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2021 70

Bayer to Raise USD3.5 Billion in Private Placement of 4.375% Bonds Due 2028 71

Bayer to Raise USD2.03 Billion in Private Placement of 1.5% bonds Due 2026 72

Bayer to Raise USD2.25 Billion in Private Placement of 3.875% Bonds Due 2023 73

Bayer to Raise USD1 Billion in Private Placement of 4.625% Bonds Due 2038 74

Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2023 75

Bayer to Raise USD870 Million in Private Placement of Bonds Due 2022 76

Bayer to Raise USD1.16 Billion in Private Placement of 0.625% bonds Due 2022 77

Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 78

Bayer Raises USD1.4 Billion in Public Offering of 2.375% Hybrid Bonds Due 2075 79

Bayer Prices 1.25% Bonds Due 2023 for USD623.5 Million 80

Bayer Raises USD1.5 Billion in Public Offering of 3% Bonds Due 2021 81

Bayer Raises USD2 Billion in Public Offering of 2.375% Bonds Due 2019 82

Bayer Raises USD500 Million in Public Offering of Notes Due 2016 83

Bayer Raises USD400 Million in Public Offering of Bonds Due 2017 84

Bayer Raises USD1.75 Billion in Public Offering of 3.375% Bonds Due 2024 85

Bayer Raises USD850 Million in Public Offering of 1.5% Bonds Due 2017 86

Bayer Raises USD2.38 Billion in Public Offering of 3% Bonds Due 2075 87

Bayer Raises USD2 Billion in Public Offering of 3.75% Bonds Due 2074 89

Bayer Raises USD677.3 Million in Public Offering of Notes Due 2016 91

Bayer Raises USD1.02 Billion in Public Offering of 1.125% Notes Due 2018 92

Bayer Raises USD1.02 Billion in Public Offering of 1.875% Bonds Due 2021 93

Bayer Completes Public Offering Of Notes Due 2019 For USD 102 Million 94

Bayer Completes Public Offering Of Notes Due 2016 For USD 259 Million 95

Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For USD 363 Million 96

Asset Transactions 97

LEO Pharma Acquires Prescription Dermatology Portfolio from Bayer 97

Recordati Acquires Consumer Health Brands from Bayer Consumer Care 98

Famar Health Care Services Acquires Pointe-Claire Manufacturing Site from Bayer 99

WellSpring Pharma Acquires Bactine 100

Alvogen Acquires Five Hormonal Products from Bayer Pharma 101

Bayer Korea to Sell Mercilon 102

Alliance Pharma Acquires Rights To Irenat From Bayer 103

Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For USD 4.8 Million 104

Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 105

Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 106

Acquisition 107

Bayer to Acquire Minority Stake in CRISPR Therapeutics for USD35 Million 107

Bayer Acquires Dihon Pharma for USD586 Million 108

Bayer Nordic Completes Acquisition Of Algeta For USD 2.58 Billion 109

Bayer Completes Acquisition Of Steigerwald Arzneimittelwerk, Herbal Treatments Provider 111

Bayer Completes Acquisition Of 96.4% Stake In Conceptus For USD 1.1 Billion 112

Delpharm Completes Acquisition Of Bayer Sante Familiale, Consumer Care Division Of Bayer 114

Nomad Bioscience Acquires Icon Genetics From Bayer Innovation 115

Bayer AG-Key Competitors 116

Bayer AG-Key Employees 117

Bayer AG-Locations And Subsidiaries 118

Head Office 118

Other Locations & Subsidiaries 118

Joint Venture 127

Recent Developments 129

Financial Announcements 129

May 03, 2018: Bayer: Operational business held back by currency effects Major progress with Monsanto acquisition 129

Oct 26, 2017: Bayer: Sales and earnings increased 133

Apr 27, 2017: Strong start to the year for Bayer 138

Corporate Communications 141

Sep 27, 2018: Bayer appoints Sebastian Guth to lead Pharmaceuticals business in the Americas 141

Sep 13, 2018: Bayer appointed Stefan Oelrich to Board of Management 142

Nov 15, 2017: Heiko Schipper is the new CEO and Head of the Consumer Health Division at Bayer 144

Sep 29, 2017: Bayer helping people affected by the earthquake in Mexico 145

Sep 12, 2017: Wolfgang Nickl to be new Chief Financial Officer at Bayer 146

Apr 27, 2017: Supervisory Board of Bayer extends service contract of CFO Johannes Dietsch to the end of May 2018 147

Jan 17, 2017: Dr. Carsten Brunn to Lead Bayer's Pharmaceuticals Business in the Americas Region 148

Legal and Regulatory 149

Sep 21, 2018: NHS wins landmark ruling against pharma companies over AMD drug 149

Aug 22, 2017: Bayer will continue to work constructively with the European Commission 150

Government and Public Interest 151

Mar 28, 2018: Life Science Leaders Gather at Medidata NEXT Basel and Frankfurt to Examine New Opportunities to Improve Clinical Development and Better Patient Lives 151

Nov 17, 2017: Christine Eischen Receives 2017 AACR-Bayer Innovation and Discovery Grant 152

Jul 18, 2017: Two Indian researchers win Grants to advance Hemophilia Research & Care 153

Jul 11, 2017: Bayer Awards $2 Million in Grants to Advance Hemophilia Research and Patient Care 155

Feb 22, 2017: Another record year for Bayer good progress with the acquisition of Monsanto 156

Product News 160

12/07/2017: Bayer to Highlight New Research on copanlisib at ASH 2017 160

11/01/2017: Janssen to Present Abstracts on XARELTO at ASH 2017 161

10/30/2017: Bayer receives FDA approval for Xarelto 10 mg once daily for the extended treatment of venous thromboembolism 165

10/25/2017: Study: Rx Drug Lawsuit Ads Cause Spike in Reports of Patient Health Incidents, Deaths 166

09/15/2017: Bayer receives positive CHMP opinion for rivaroxaban 10 mg once daily for the extended prevention of venous thromboembolism 167

09/14/2017: Bayer Receives FDA Approval for Aliqopa (copanlisib) 60 mg vial for Injection in Adults with Relapsed Follicular Lymphoma after Two Prior Systemic Therapies 169

08/22/2017: Landmark GARFIELD-AF Data to be Presented at ESC 2017 Congress Will Feature 1-year Outcomes on 52,000 Prospective Patients and the First Insights From the Registry on Health Economics in Atrial Fibrillation (AF) 170

07/26/2017: Compugen Provides Update on its Immuno-Oncology Drug Candidate CGEN-15001T 173

07/21/2017: Bayers Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent Placement 174

07/02/2018: Compugen Welcomes FDA Clearance of Bayer's IND Application for BAY 1905254 176

06/28/2017: U.S. FDA Grants Priority Review of XARELTO (rivaroxaban) sNDA for a 10 mg Dose to Reduce the Risk of Recurrent Venous Thromboembolism 177

05/17/2018: Bayer to Present One Poster on Rogaratinib at ASCO 2018 179

05/17/2017: Bayer Receives FDA Priority Review For Investigational Anti-Cancer Compound Copanlisib 180

03/18/2017: Bayer's Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study 182

Product Approvals 184

Dec 11, 2017: Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD) 184

Nov 06, 2017: Bayer Submits Application for Marketing Approval of Rivaroxaban for Patients with Coronary or Peripheral Artery disease to European Medicines Agency 185

Apr 28, 2017: Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism 187

Clinical Trials 189

Oct 09, 2018: Bayer to showcase latest oncology research on copanlisib at ESMO 2018 Congress 189

May 17, 2018: Bayer to Present on Copanlisib Hydrochloride at ASCO 2018 190

Apr 18, 2018: Evotec and Bayer advance third endometriosis programme into Phase I clinical development 191

Apr 17, 2018: Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy 192

Dec 07, 2017: Thirteen abstracts highlighting data from Bayer's rivaroxaban will be presented at ASH 2017, two addressing cancer-associated thrombosis 193

Nov 10, 2017: Bayers Xarelto(rivaroxaban) Significantly Reduces the Risk of Major Amputation by 70% in Patients with Peripheral Artery Disease 195

Oct 05, 2017: Bayers NAVIGATE ESUS study halted early as it indicated comparable efficacy between treatment arms 196

Sep 01, 2017: Bayer to Present Data on Copanlisib at ESMO 2017 Congress 197

Sep 01, 2017: Bayer to Present Data on Rogaratinib at ESMO 2017 Congress 198

Aug 27, 2017: Bayer's Xarelto significantly lowered the combined risk of stroke, cardiovascular death and heart attack in patients with chronic coronary or peripheral artery disease by 24% 199

Aug 21, 2017: New XARELTO (rivaroxaban) Data at ESC Congress 2017 Includes Late-Breaking Results from Landmark Phase 3 COMPASS Study 201

Jul 24, 2017: Evotec and Bayer Advance Endometriosis Programme into Phase I Clinical Development and Extend Alliance 207

Jul 03, 2017: New Data from Bayers Portfolio in Thrombosis and Hemophilia to be Presented at ISTH 2017 208

Mar 31, 2017: Phase II Copanlisib Data Show Durable Tumor Response in Indolent Non-Hodgkins Lymphoma 210

Mar 06, 2017: EINSTEIN CHOICE Study with Bayer's Rivaroxaban Accepted for Late-Breaking Clinical Trial Presentation at ACC.17 212

Feb 08, 2017: Phase III COMPASS study with Bayer's Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early 215

Other Significant Developments 217

Oct 17, 2018: Bayer provides disaster reliefImmediate support for earthquake victims in Indonesia company makes EUR 115,000 available in immediate assistance for people impacted in Central Sulawesi province 217

Aug 30, 2018: Bayer accelerates six new startups 218

May 31, 2018: ORNL ramps up production of key radioisotope for cancer-fighting drug 219

Dec 01, 2017: Bayer invests in differentiated drug pipeline with over 50 projects focused on high unmet medical needs 220

Appendix 223

Methodology 223

About GlobalData 223

Contact Us 223

Disclaimer 223


List Of Figure

List of Figures

Bayer AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Bayer AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10

Bayer AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 11

Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12

Bayer AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 13

Bayer AG, Medical Devices Deals, 2012 to YTD 2018 15


List Of Table

List of Tables

Bayer AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10

Bayer AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 11

Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12

Bayer AG, Deals By Therapy Area, 2012 to YTD 2018 13

Bayer AG, Medical Devices Deals, 2012 to YTD 2018 15

Bayer AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 16

Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 20

BlueRock Therapeutics Raises USD225 Million in Series A Financing 22

Bayer to Raise USD3.69 Billion in Private Placement of Shares 23

Bayer May Sell Dermatology Business 25

Sobera Capital Acquires Minority Stakes In Biopharma Companies From Bayer Pharma And Bayer HealthCare 26

ChromoTek Enters Into Licensing Agreement With Bayer For Cell Cycle Chromobody Technology 27

Bayer and MD Anderson Cancer Center Enter into Agreement 28

Bayer and PeptiDream Enter into Partnership 29

Bayer Enters into Co-Development Agreement with Loxo Oncology 30

Bayer and Vanderbilt University Medical Center Enter into Research Agreement 31

leadXpro Enters into Agreement with Bayer 32

University of Pittsburgh and Bayer Form Research Collaboration Agreement 33

Bayer Enters into Partnership with Evotec 34

Bayer Enters into Agreement with National Surgical Adjuvant Breast and Bowel Project 35

Bayer Enters into Co-Development Agreement with Regeneron Pharma 36

Bayer and CRISPR Therapeutics Forms Joint Venture 37

Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 38

Proteros Biostructures Enters into Research Agreement with Bayer 39

Bayer HealthCare Enters Co-Development Agreement with University of Oxford 40

Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 41

arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 42

Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 43

Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 44

Bayer HealthCare Pharma And Broad Institute Enter Into Agreement To Develop Cancer Therapy 45

Bayer Enters Into Co-Marketing Agreement With Ildong Pharma For OTC Drugs 46

Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 47

Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 48

X-Chem and Bayer Pharma Expand Agreement 49

Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 50

Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 51

Algeta Exercises Option Agreement With Bayer To Co-Promote Alpharadin 53

Bayer Healthcare Enters Into Co-Development Agreement With Tsinghua University 54

Bayer Enters into Licensing Agreement with Haplogen and Evotec 55

Luye Pharma and Luye Supply to Enter into Agreement with Bayer 56

Bayer Enters into Licensing Agreement with Progenics Pharma 57

X-Chem Enters into Licensing Agreement with Bayer Pharma for Drug Discovery Program 58

Taisho Pharma Enters into Licensing Agreement with Bayer Yakuhin 59

Bayer Enters into Licensing Agreement with ERS Genomics 60

Bayer Pharma Enters Into Licensing Agreement With X-Chem For Drug Discovery Program 61

Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library 62

Oxford Pharmascience Enters Into Licensing Agreement With Bayer Consumer Care 63

Bayer Plans to Raise USD7 Billion in Rights Offering of Shares 64

Crispr Therapeutics Prices Private Placement of Shares for USD35 Million 65

Bayer to Raise USD2.5 Billion in Private Placement of 4.25% Bonds Due 2025 66

Bayer to Raise USD1.74 Billion in Private Placement of 2.125% bonds Due 2029 67

Bayer to Raise USD1.25 Billion in Private Placement of 3.5% Bonds Due 2021 68

Bayer to Raise USD2 Billion in Private Placement of 4.875% Bonds Due 2048 69

Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2021 70

Bayer to Raise USD3.5 Billion in Private Placement of 4.375% Bonds Due 2028 71

Bayer to Raise USD2.03 Billion in Private Placement of 1.5% bonds Due 2026 72

Bayer to Raise USD2.25 Billion in Private Placement of 3.875% Bonds Due 2023 73

Bayer to Raise USD1 Billion in Private Placement of 4.625% Bonds Due 2038 74

Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2023 75

Bayer to Raise USD870 Million in Private Placement of Bonds Due 2022 76

Bayer to Raise USD1.16 Billion in Private Placement of 0.625% bonds Due 2022 77

Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 78

Bayer Raises USD1.4 Billion in Public Offering of 2.375% Hybrid Bonds Due 2075 79

Bayer Prices 1.25% Bonds Due 2023 for USD623.5 Million 80

Bayer Raises USD1.5 Billion in Public Offering of 3% Bonds Due 2021 81

Bayer Raises USD2 Billion in Public Offering of 2.375% Bonds Due 2019 82

Bayer Raises USD500 Million in Public Offering of Notes Due 2016 83

Bayer Raises USD400 Million in Public Offering of Bonds Due 2017 84

Bayer Raises USD1.75 Billion in Public Offering of 3.375% Bonds Due 2024 85

Bayer Raises USD850 Million in Public Offering of 1.5% Bonds Due 2017 86

Bayer Raises USD2.38 Billion in Public Offering of 3% Bonds Due 2075 87

Bayer Raises USD2 Billion in Public Offering of 3.75% Bonds Due 2074 89

Bayer Raises USD677.3 Million in Public Offering of Notes Due 2016 91

Bayer Raises USD1.02 Billion in Public Offering of 1.125% Notes Due 2018 92

Bayer Raises USD1.02 Billion in Public Offering of 1.875% Bonds Due 2021 93

Bayer Completes Public Offering Of Notes Due 2019 For USD 102 Million 94

Bayer Completes Public Offering Of Notes Due 2016 For USD 259 Million 95

Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For USD 363 Million 96

LEO Pharma Acquires Prescription Dermatology Portfolio from Bayer 97

Recordati Acquires Consumer Health Brands from Bayer Consumer Care 98

Famar Health Care Services Acquires Pointe-Claire Manufacturing Site from Bayer 99

WellSpring Pharma Acquires Bactine 100

Alvogen Acquires Five Hormonal Products from Bayer Pharma 101

Bayer Korea to Sell Mercilon 102

Alliance Pharma Acquires Rights To Irenat From Bayer 103

Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For USD 4.8 Million 104

Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 105

Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 106

Bayer to Acquire Minority Stake in CRISPR Therapeutics for USD35 Million 107

Bayer Acquires Dihon Pharma for USD586 Million 108

Bayer Nordic Completes Acquisition Of Algeta For USD 2.58 Billion 109

Bayer Completes Acquisition Of Steigerwald Arzneimittelwerk, Herbal Treatments Provider 111

Bayer Completes Acquisition Of 96.4% Stake In Conceptus For USD 1.1 Billion 112

Delpharm Completes Acquisition Of Bayer Sante Familiale, Consumer Care Division Of Bayer 114

Nomad Bioscience Acquires Icon Genetics From Bayer Innovation 115

Bayer AG, Key Competitors 116

Bayer AG, Key Employees 117

Bayer AG, Subsidiaries 118

Bayer AG, Joint Venture 127

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Bayer AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.